CLINICAL EFFICACY OF GLYCOSAMINOGLYCANS IN PATIENTS WITH DIABETES MELLITUS AND ISCHEMIC HEART DISEASE

Aim. To study sulodexide clinical efficacy in patients with type 2 diabetes mellitus (DM) and ischemic heart disease (IHD) in prevention of contrast induced nephropathy (CIN). Material and мethods. Patients with type 2 DM and IHD who undergone X-Ray contrast intervention. The patients were randomized into 2 groups: 56 patients of the main group were i/v administered sulodexide (Vessel Due F , “Alfa Wassermann”, Italy) according to standard procedure; 56 patients of the control group were treated with unfractionated heparin. Results. The incidence of CIN in the main and control groups was, respectively , 16% and 42% (p<0.01). Reduction of microalbuminuria (MAU) was found in 89.3% of the sulodexide group patients. MAU dynamics in patients of control group was not observed. There were no deteriorations in echocardiography characteristics in patients of both groups. The reduction in  low density cholesterol and triglyceride plasma levels was observed in the main group. Sulodexide induced a lengthening of the activated partial thromboplastin time (from 30±0.6 to 34±0.5 s), without altering fibrinogen level. There were no thrombotic and hemorrhagic complications of endovascular intervention in sulodexide group. No one case of thrombocytopenia was observed. Higher risk of CIN in patients without sulodexide treatment compared with this in sulodexide treated patients was associated with multiple lesions of coronary arteries, diuretic intake in periprocedural period, contrast agent dose, duration of hospitalization, seriousness of intervention. Conclusion. Sulodexide therapy in patients with 2 type DM and IHD undergone X-Ray contrast intervention prevents renal dysfunction, providing antiproteinuric effect and correcting lipid metabolism and coagulation system disturbances.

1. Volgina G.V . Contrast-induced nephropathy: pathogenesis, risk factors, prevention strategy. Shkola nefrologa 2006;8(2):176-183. Russian (Волгина Г .В. Контраст-индуцированная нефропатия: патогенез, факторы риска, стратегия профилактики. Школа нефролога 2006;8(2):176-183).

2. Savchenko A.P . Interventional Cardiology. Coronary angiography and stenting: a clinical guide. Mosscow: GEOTAR – Media; 2010. Russian (Савченко А.П. Интервенционная кардиология. Коронарная ангиография и стентирование: руководство. М.: ГЭОТАР – Медиа; 2010).

3. Karmazanovskiy G.G. Modern X-ray contrast media and nephropathy: how to reduce the risk of developing kidney failure? Meditsinskaya vizualizatsiya 2007; 1: 135-144. Russian (Кармазановский Г .Г . Современные рентген-контрастные вещества и нефропатия: как снизить риск развития почечной недостаточности? Медицинская визуализация 2007; 1: 135-144).

4. Gaddi A.V., Cicero A.F ., Gambaro G. Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered. Int J Nephrol Renovasc Dis 2010; 3: 99-105.

5. Goh S.Y , Jasik M, Cooper M.E. Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs 2008; 13(3): 447-63.

6. Goldenberg I., Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005; 172(11):1461-1471.

7. Lameire N.H. Contrast-induced nephropathy—prevention and risk reduction. Nephrol Dial Transplant 2006; 21:111-123.

8. Martínez Castelao A. Advances in diabetes mellitus, diabetic nephropathy , metabolic syndrome and cardio-vascular-renal risk. Nefrologia 2008; 28 Suppl 5: 79-84.

9. Mehran R. Contrast-induced nephropathy: Definition, epidemiology and patients risk. Kidney Int 2006; Suppl: 11-15.

10. Nikolsky E. Understanding the consequences of contrast – induced nephropathy. Rev Cardiovasc Med 2003; 4 Suppl 5: 10-18.

11. Ofosu F .A. Pharmacological actions of sulodexide. Semin Thromb Hemost 1998; 24: 127-138. litus, renal insufficiency , or both. A prospective controlled study. N Engl J Med 1989; 320: 143-149.

12. Ravera M., Re M., Weiss U., Deferrari L. et al. Emerging therapeutic strategies in diabetic nephropathy. J Nephrol 2007; 20 Suppl 12: S23-32.

13. Rihal C.S. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264.

14. Solomon R. Consensus panel for CIN. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int 2006; 100 Suppl: 51-53.

15. Valociková I. Sulodexide and nephrotic syndrome in patients with diabetic nephropathy. Vnitr Lek 2011; 57(5):507-10.

16. Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs 2007; 67(18): 2681-96.

17. Weisboard S.D. Radiocontrast–induced acute renal failure. J Intensive Care Med 2005; 20: 63-75.

18. Weiss R., Niecestro R., Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs 2007; 67(18): 2681-96.

19. National guidelines for diagnosis and treatment of hypertension. The Experts Commit tee of RMSAH and RSSC. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7(6) prilozhenie 2:1-32. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Комитет экспертов РМО-АГ и ВНОК. Кардиоваскулярная терапия и профилактика 2008; 7(6) приложение 2:1-32).

20. National guidelines for diagnosis and treatment of hypertension. The Experts Commit tee of RMSAH and RSSC. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7(6) prilozhenie 2:1-32. Russian (Национальные рекомендации по диагностике и лечению стабильной стенокардии. Комитет экспертов ВНОК. Кардиоваскулярная терапия и профилактика 2008; 7(6) приложение 4:1-35).